Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This 22 week study will assess the efficacy, safety, and tolerability of LDE225 versus vehicle when applied topically to basal cell carcinoma (BCC) in patients with NBCCS. Patients will treat multiple BCCs for up to 12 weeks. Treatment success is defined as complete clinical clearance and complete histological clearance in BCCs.
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
A Randomized, Double-blind, Vehicle-controlled, Multicenter Trial of Topically Administered LDE225 Cream (0.75% Bid) to Evaluate Clearance of Basal Cell Carcinoma in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome
Resource links provided by the National Library of Medicine
To demonstrate superiority of topical LDE225 versus vehicle in terms of treatment success in patients with NBCCs. Measure: Complete clinical clearance and complete histological clearance of BCCs [ Time Frame: 4 weeks after LDE225 treatment ]
Secondary Outcome Measures :
To assess the safety of topical treatment with LDE225, compared to vehicle. Measure: Reported systemic adverse events in patients with NBCCS [ Time Frame: Treatment phase and up to 4 weeks after LDE225 treatment ]
To evaluate the local tolerability of topical treatment with LDE225, compared to vehicle. Measure:Reported local adverse events in patients with NBCCS [ Time Frame: Treatment phase and up to 4 weeks after LDE225 treatment ]
To assess the rate of complete clinical clearance of BCCs in patients with NBCCS. Measure: No clinical residual signs of carcinoma [ Time Frame: 4 weeks after LDE225 treatment ]
To assess the rate of complete histological clearance of BCCs in patients with NBCCS. Measure: No residual tumor tissue [ Time Frame: 4 weeks after LDE225 treatment ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult greater than 18 years old, male or female.
Patient must be able to understand and communicate with the investigator and comply with the requirements of the study.
Typical presentation of NBCCS in the opinion of the investigator
At least one of the major clinical criteria of NBCCS.
Multiple BCCs during the screening period
Any concomitant dermatological disease that could confound the evaluations, based on the discretion of the investigator.
Prior exposure to LDE225.
Use of systemic treatment for BCC in the 4 weeks prior to Baseline.
Use of topical treatment or photodynamic therapy (PDT) in the 12 weeks prior to Baseline.
Use of other investigational drugs at Baseline, or within 30 days or 5 half-lives prior to Baseline, whichever is longer.
Clinically significant medical condition, as per judgment of the investigator.
History of hypersensitivity to any of the ingredient of the study drug.
Pregnant or nursing (lactating) women
Women of child-bearing potential and fertile males, UNLESS they are using two birth control methods
Other protocol-defined inclusion/exclusion criteria may apply